SOAT1 and psoriasis: This blockade inhibits downstream signal transduction and signal transducers and activators of transcription (STAT)‐dependent gene transcription.[8] The Janus kinase (JAK)‐STAT pathway is engaged at various points within the interleukin‐23 (IL‐23)/T helper 17 (Th17) signaling pathway, which is considered central to the pathogenesis of psoriasis.[9] Deu may provide an improved therapeutic index and reduce the toxicities associated with pan‐JAK inhibitors, as it demonstrates ≈100‐ to 200‐fold greater selectivity for JAK1/JAK3 and over 3000‐fold greater selectivity for JAK2.[10, 11]